(RVMD) Revolution Medicines - Ratings and Ratios
Targeted Therapies, RAS Inhibitors, Cancer Treatments
RVMD EPS (Earnings per Share)
RVMD Revenue
Description: RVMD Revolution Medicines July 25, 2025
Revolution Medicines Inc (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The companys pipeline includes RAS(ON) inhibitors and RAS companion inhibitors, which are designed to be used as monotherapy or in combination with other therapeutic agents.
The companys RAS(ON) inhibitors, such as daraxonrasib, elironrasib, and zoldonrasib, are in Phase 1 clinical trials, while its RAS companion inhibitors, including RMC-4630 and RMC-5552, are in Phase 2 and Phase 1 clinical trials, respectively. The companys pipeline is diverse, with multiple candidates targeting different RAS variants, including G12C, G12V, Q61H, and G13C.
From a financial perspective, RVMD has a market capitalization of approximately $7.27 billion, indicating a significant presence in the biotechnology sector. The companys Return on Equity (ROE) is -37.06%, which is expected given its clinical-stage status and ongoing investment in research and development. Key Performance Indicators (KPIs) to monitor include the progress of its clinical trials, particularly the Phase 1 and Phase 2 trials for its lead candidates, as well as its cash burn rate and ability to secure future funding.
In terms of valuation, RVMDs stock price has fluctuated, with a 52-week high of $60.60 and a low of $31.13. The current price is around $37.53, with a 20-day Simple Moving Average (SMA) of $37.79, indicating a relatively stable short-term trend. Investors should monitor the companys progress in its clinical trials, as well as industry trends and competitor activity, to assess the potential for future growth.
RVMD Stock Overview
| Market Cap in USD | 10,113m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-02-13 |
RVMD Stock Ratings
| Growth Rating | 39.3% |
| Fundamental | 29.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -2.57% |
| Analyst Rating | 4.67 of 5 |
RVMD Dividends
Currently no dividends paidRVMD Growth Ratios
| Growth Correlation 3m | 93% |
| Growth Correlation 12m | -34.1% |
| Growth Correlation 5y | 34.9% |
| CAGR 5y | 38.13% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.78 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.02 |
| Sharpe Ratio 12m | -0.20 |
| Alpha | -5.44 |
| Beta | 1.264 |
| Volatility | 52.45% |
| Current Volume | 1972.7k |
| Average Volume 20d | 1934.4k |
| Stop Loss | 52.1 (-4.4%) |
| Signal | 0.21 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-812.1m TTM) > 0 and > 6% of Revenue (6% = 15.7m TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA -0.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 761.5% (prev 204.8k%; Δ -204.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.28 (>3.0%) and CFO -684.9m > Net Income -812.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.1m) change vs 12m ago 13.93% (target <= -2.0% for YES) |
| Gross Margin -110.0% (prev -50.5k%; Δ 50.3kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.35% (prev 0.04%; Δ 12.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -998.3 (EBITDA TTM -883.7m / Interest Expense TTM 899.0k) >= 6 (WARN >= 3) |
Altman Z'' -4.51
| (A) 0.82 = (Total Current Assets 2.18b - Total Current Liabilities 184.5m) / Total Assets 2.43b |
| (B) -0.91 = Retained Earnings (Balance) -2.20b / Total Assets 2.43b |
| (C) -0.42 = EBIT TTM -897.5m / Avg Total Assets 2.12b |
| (D) -3.90 = Book Value of Equity -2.20b / Total Liabilities 564.2m |
| Total Rating: -4.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.16
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -8.64% = -4.32 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda 0.31 = 2.43 |
| 6. ROIC - WACC (= -56.77)% = -12.50 |
| 7. RoE -41.78% = -2.50 |
| 8. Rev. Trend -24.22% = -1.82 |
| 9. EPS Trend 7.34% = 0.37 |
What is the price of RVMD shares?
Over the past week, the price has changed by +0.70%, over one month by +25.13%, over three months by +46.37% and over the past year by +15.30%.
Is Revolution Medicines a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RVMD is around 52.57 USD . This means that RVMD is currently overvalued and has a potential downside of -3.51%.
Is RVMD a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RVMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.3 | 40.1% |
| Analysts Target Price | 76.3 | 40.1% |
| ValueRay Target Price | 59.7 | 9.6% |
RVMD Fundamental Data Overview October 20, 2025
P/S = 9035.0954
P/B = 4.5797
Beta = 1.264
Revenue TTM = 261.6m USD
EBIT TTM = -897.5m USD
EBITDA TTM = -883.7m USD
Long Term Debt = 132.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 132.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -269.7m USD (from netDebt column, last quarter)
Enterprise Value = 8.11b USD (10.11b + Debt 132.8m - CCE 2.14b)
Interest Coverage Ratio = -998.3 (Ebit TTM -897.5m / Interest Expense TTM 899.0k)
FCF Yield = -8.64% (FCF TTM -700.4m / Enterprise Value 8.11b)
FCF Margin = -267.7% (FCF TTM -700.4m / Revenue TTM 261.6m)
Net Margin = -310.4% (Net Income TTM -812.1m / Revenue TTM 261.6m)
Gross Margin = -110.0% ((Revenue TTM 261.6m - Cost of Revenue TTM 549.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.34 (Enterprise Value 8.11b / Total Assets 2.43b)
Interest Expense / Debt = 0.68% (Interest Expense 899.0k / Debt 132.8m)
Taxrate = -0.13% (negative due to tax credits) (753.0k / -600.8m)
NOPAT = -898.6m (EBIT -897.5m * (1 - -0.13%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 11.79 (Total Current Assets 2.18b / Total Current Liabilities 184.5m)
Debt / Equity = 0.07 (Debt 132.8m / totalStockholderEquity, last quarter 1.87b)
Debt / EBITDA = 0.31 (negative EBITDA) (Net Debt -269.7m / EBITDA -883.7m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -269.7m / FCF TTM -700.4m)
Total Stockholder Equity = 1.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -33.42% (Net Income -812.1m / Total Assets 2.43b)
RoE = -41.78% (Net Income TTM -812.1m / Total Stockholder Equity 1.94b)
RoCE = -43.22% (EBIT -897.5m / Capital Employed (Equity 1.94b + L.T.Debt 132.8m))
RoIC = -46.23% (negative operating profit) (NOPAT -898.6m / Invested Capital 1.94b)
WACC = 10.54% (E(10.11b)/V(10.25b) * Re(10.67%) + D(132.8m)/V(10.25b) * Rd(0.68%) * (1-Tc(-0.00)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.44%
Fair Price DCF = unknown (Cash Flow -700.4m)
EPS Correlation: 7.34 | EPS CAGR: 24.20% | SUE: 4.0 | # QB: 1
Revenue Correlation: -24.22 | Revenue CAGR: -80.64% | SUE: -4.0 | # QB: 0
Additional Sources for RVMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle